Science Friday How Scientists Made The First Gene-Editing Treatment For A Baby
14 snips
Jun 25, 2025 
Dr. Kiran Musunuru, a leader in translational research, and Dr. Rebecca Ahrens-Nicklas, a pediatrician focused on genetics, join the discussion about a groundbreaking gene-editing treatment for a baby with a life-threatening disorder. They explain how CRISPR technology was tailored specifically for this case and share the emotional journey of the family involved. The conversation also touches on the scalability of such treatments, funding challenges, and the critical role of responsible media coverage in shaping public understanding of this medical advancement.
AI Snips
Chapters
Transcript
Episode notes
CRISPR Delivery and Risks
- CRISPR therapy is delivered to liver cells via tiny lipid nanoparticles, targeting the organ that processes blood toxins.
- Major risks include allergic reactions and liver stress; prior adult trials noted general safety but infant effects are less known.
Partial Liver Correction Suffices
- Therapeutic benefit usually requires correcting only a fraction of liver cells for metabolic diseases.
- Whole liver correction isn't always necessary, easing treatment goals for many disorders.
Genome Sequencing Improves CRISPR Safety
- CRISPR's 'GPS' can mis-target, so researchers used KJ's full genome to ensure editing hit only the intended site.
- Personalized genome mapping greatly reduces off-target risks in gene editing treatments.